A double‐blind, placebo‐controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis
- 1 December 1989
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 39 (12) , 1635
- https://doi.org/10.1212/wnl.39.12.1635
Abstract
We performed a 3-month, double-blind, placebo-controlled trial of 300 mg of gangliosides (Cronassial) in 40 outpatients with amyotrophic lateral sclerosis (ALS). We evaluated drug effect through physical examinations and symptom scales. Though this dosage had no major toxic effect, Cronassial treatment did not significantly benefit ALS patients.This publication has 5 references indexed in Scilit:
- Double‐blind controlled trials of Cronassial in chronic neuromuscular diseases and ataxiaNeurology, 1988
- Trial of ganglioside therapy for diabetic neuropathyMuscle & Nerve, 1987
- Ganglioside therapy in diabetic neuropathyMuscle & Nerve, 1986
- Electromyographic study of diabetic and alcoholic polyneuropathic patients treated with gangliosidesMuscle & Nerve, 1982
- Effects of Cerebral Gangliosides in the Alcoholic PolyneuropathiesEuropean Neurology, 1980